Farmaforum 2024

26 Sept 2024 | Madrid, Spain

ProductUpdated on 11 September 2024

METHOD OF PREDICTION OR PROGNOSIS OF RISK OF RETURN IN PATIENTS WITH GERM CELL TUMORS WITHOUT SEMINOMA AFTER ORCHIECTOMY

Ana Somé

Technology Transfer Manager - Specialist on Intellectual Property at Universidad de Málaga

Málaga, Spain

About

Currently, 90% of cancerous testicular tumors originate in germ cells, the most frequent tumors being in young men. These, in turn, can be seminoma and non-seminoma cells, occurring in a similar number of times to those developed in one or another type of cell. Non-seminoma germ cell tumors tend to have a faster growth rate than seminomas. The general treatment for this type of cancer is orchiectomy, however, a percentage of these patients relapse and need adjuvant therapy in their treatment. To determine which patients have a higher risk of relapse and proceed to a more appropriate and personalized treatment, a method has been developed based on the expression of a set of genes, which allows selecting those patients with a higher risk of relapse to give them adjuvant treatment . This invention allows the detection of patients with higher and lower risk of relapse, as well as the development of a kit that allows and makes the detection of this risk faster.

Advantages

This method has the following advantages: - Avoid overtreatment in patients who do not need adjuvant treatment. - Focus health resources in a more specialized way. - Provide information on the probability of recurrence in a more complete way than the current parameters.

Uses and Applications

Invention of the biomedical sector. Diagnosis and prognosis in the area of oncology, more specifically for testicular cancers.

Looking for

  • Other

Applies to

  • Pharmaceutical industry
  • Health innovation

Similar opportunities